We provide you with 20 years of free, institutional-grade data for ALXO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ALXO. Explore the full financial landscape of ALXO stock.
| Reported Date | CIK | Ticker | Type |
|---|
ALX Oncology Holdings Inc(NASDAQ:ALXO) 
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the ...
Website: http://alxoncology.com
Founded: 2015
Full Time Employees: 17
CEO: Jaume Pons
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about ALXO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.